Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans.
暂无分享,去创建一个
[1] M. Kreissl,et al. Favourable course of disease after incomplete remission on 131I therapy in children with pulmonary metastases of papillary thyroid carcinoma: 10 years follow-up , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[2] S. Larson,et al. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[3] M. Mete,et al. Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in the Identification of Metastasis in Differentiated Thyroid Cancer with 131I Planar Whole-Body Imaging and 124I PET , 2012, The Journal of Nuclear Medicine.
[4] Q. Duh,et al. Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high- and low-risk patients. , 1999, Surgery.
[5] M. Ashcraft,et al. The comparative value of serum thyroglobulin measurements and iodine 131 total body scans in the follow-up study of patients with treated differentiated thyroid cancer. , 1981, The American journal of medicine.
[6] A. Pinchera,et al. Serum and tissue thyroglobulin measurement: clinical applications in thyroid disease. , 1999, Biochimie.
[7] I. Hay,et al. Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131 diagnostic scan-negative metastases: including comments on the role of serum thyroglobulin monitoring in tumor surveillance. , 2000, Seminars in nuclear medicine.
[8] Stephanie L. Lee,et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.
[9] R. Cavalieri. Nuclear imaging in the management of thyroid carcinoma. , 1996, Thyroid : official journal of the American Thyroid Association.
[10] E. Baudin,et al. 131I therapy for elevated thyroglobulin levels. , 1997, Thyroid : official journal of the American Thyroid Association.
[11] E. Baudin,et al. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. , 2003, The Journal of clinical endocrinology and metabolism.
[12] M. Schlumberger,et al. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[13] Eun Sook Kim,et al. Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole‐body scan: comparative study , 2003, Clinical endocrinology.
[14] H. Boezen,et al. Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin. , 2003, European journal of endocrinology.
[15] A. Alzahrani,et al. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer , 2005, Journal of endocrinological investigation.
[16] M. Chao. Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan. , 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).
[17] Jeong Hyun Lee,et al. Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography scan. , 2010, The Journal of clinical endocrinology and metabolism.